Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

NCT06067295 | Recruiting DMC

• 3 other identifiers: 4P-22-2NCI-2023-01434P30CA014089
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 2

Brief Summary

This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, diet, and quality of life) researchers hope to learn more about prostate cancer and ways to improve outcomes in the future.

Conditions

Prostate Carcinoma

Outcome Measures

Primary Outcomes (1)

• Collection of biological specimens and clinical data for future research related to prostate cancer.

  The objective of this study is to create a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.

  Up to 5 years

Study Arms (1)

Observational

Patients undergo blood and urine sample collection, complete surveys, and have their medical records reviewed on study.

Other: Non-Interventional Study

Interventions

Non-Interventional Study OTHER

Non-interventional study

Observational

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult men diagnosed with advanced (metastatic) prostate cancer at Norris Comprehensive Cancer Center and Los Angeles General Medical Center with either metastatic castrate sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC).

You may qualify if:

• Men of all racial and ethnic groups 18 years of age or older
• Men with a diagnosis of advanced (metastatic) prostate cancer who are scheduled to begin a new systemic treatment (including first or subsequent lines of therapy)
• Prior participation on clinical trials is allowed

You may not qualify if:

• Inability to give informed consent
• Any other malignancy, unless previously treated with curative intent and the subject has been disease free for 3 years or longer

Sponsors & Collaborators

• University of Southern California: lead
• National Cancer Institute (NCI): collaborator

Study Sites (2)

Los Angeles General Medical Center

Los Angeles, California, 90033, United States

RECRUITING

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Tissue, blood, and urine

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Amir Goldkorn, MD

  University of Southern California

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Cheryl Kefauver, RN

CONTACT

323-865-0459; Cheryl.Kefauver@med.usc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 27, 2023
• First Posted: October 4, 2023
• Study Start: February 21, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: March 10, 2026

Record last verified: 2026-03

Locations

US (2)